儿童自身免疫性血细胞减少症脾切除术后长期结局的决定因素
基于法国OBS'CEREVANCE前瞻性队列161例自身免疫性血细胞减少症患儿,脾切除术后中位随访6.8年,发现免疫病理表现与无失败生存率降低相关,且与复发或严重细菌感染及血栓风险升高相关。
要点
- 脾切除术前诊断免疫病理表现与较低无失败生存率相关(HR 0.39)。
- 随访期间任何时候诊断免疫病理表现与更低无失败生存率相关(HR 0.22)。
- 免疫病理表现还与复发或严重细菌感染及血栓风险升高相关。
核心结论
- 结果支持在考虑脾切除时寻找相关免疫病理表现以细化风险获益比。
- 术后监测免疫病理表现有助于识别不良结局风险较高的患者。
研究设计与样本
- OBS'CEREVANCE队列自2004年起前瞻性纳入法国自身免疫性血细胞减少症患儿。
- 纳入161例患者(慢性免疫性血小板减少症120例,自身免疫性溶血性贫血19例,Evans综合征22例)。
- 脾切除术后中位随访6.8年(范围1.0-33.3年)。
- 主要结局为无失败生存期,定义为从脾切除至开始二线治疗(除类固醇和静脉免疫球蛋白外)或死亡的时间。
主要发现
- 自身免疫性血细胞减少症亚型与无失败生存期无关。
- 脾切除术前诊断免疫病理表现与较低无失败生存期相关(HR 0.39;95%CI 0.21-0.72;P=0.003;按亚型调整)。
- 随访期间任何时候诊断免疫病理表现与更低无失败生存期相关(HR 0.22;95%CI 0.12-0.39;P=2.8×10^-7;按亚型调整)。
- 随访期间任何时候诊断免疫病理表现还与复发或严重细菌感染风险升高及血栓风险升高相关。
临床怎么用
- 作者认为,在考虑脾切除时应寻找相关免疫病理表现以细化风险获益比。
- 作者认为,术后监测免疫病理表现有助于识别不良结局风险较高的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Splenectomy is effective in ∼70% to 80% of pediatric chronic immune thrombocytopenia (cITP) cases, and few data exist about it in autoimmune hemolytic anemia (AIHA) and Evans syndrome (ES). Because of the irreversibility of the procedure and the lack of predictions regarding long-term outcomes, the decision to undertake splenectomy is difficult in children. We report here factors associated with splenectomy outcomes from the OBS'CEREVANCE cohort, which prospectively includes French children with autoimmune cytopenia (AIC) since 2004. The primary outcome was failure-free survival (FFS), defined as the time from splenectomy to the initiation of a second-line treatment (other than steroids and intravenous immunoglobulins) or death. We included 161 patients (cITP, n = 120; AIHA, n = 19; ES, n = 22) with a median (minimum-maximum) follow-up of 6.8 years (1.0-33.3) after splenectomy. AIC subtype was not associated with FFS. We found that immunopathological manifestations (IMs) were strongly associated with unfavorable outcomes. Diagnosis of an IM before splenectomy was associated with a lower FFS (hazard ratio [HR], 0.39; 95% confidence interval [CI], 0.21-0.72, P = .003, adjusted for AIC subtype). Diagnosis of an IM at any timepoint during follow-up was associated with an even lower FFS (HR, 0.22; 95% CI, 0.12-0.39; P = 2.8 × 10-7, adjusted for AIC subtype) as well as with higher risk of recurrent or severe bacterial infections and thrombosis. In conclusion, our results support the search for associated IMs when considering a splenectomy to refine the risk-benefit ratio. After the procedure, monitoring IMs helps to identify patients with higher risk of unfavorable outcomes.
引用
- Pincez T, Aladjidi N, Héritier S, et al. Determinants of long-term outcomes of splenectomy in pediatric autoimmune cytopenias. Blood. 2022. PMID: 35443028. doi:10.1182/blood.2022015508
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。